Aspergillosis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Aspergillosis – Pipeline Review, H1 2017’, provides an overview of the Aspergillosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Aspergillosis

The report reviews pipeline therapeutics for Aspergillosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Aspergillosis therapeutics and enlists all their major and minor projects

The report assesses Aspergillosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Aspergillosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Aspergillosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amplyx Pharmaceuticals Inc

Astellas Pharma Inc

Biomar Microbial Technologies

Biosergen AS

Cidara Therapeutics Inc

F2G Ltd

Hsiri Therapeutics LLC

iCo Therapeutics Inc.

Matinas BioPharma Holdings Inc

Merck & Co Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Sigma-Tau SpA

Vical Inc

Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aspergillosis - Overview

Aspergillosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Aspergillosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aspergillosis - Companies Involved in Therapeutics Development

Amplyx Pharmaceuticals Inc

Astellas Pharma Inc

Biomar Microbial Technologies

Biosergen AS

Cidara Therapeutics Inc

F2G Ltd

Hsiri Therapeutics LLC

iCo Therapeutics Inc.

Matinas BioPharma Holdings Inc

Merck & Co Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Sigma-Tau SpA

Vical Inc

Visterra Inc

Aspergillosis - Drug Profiles

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-9726 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspergillus fumigatus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BSG-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

celastrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-901318 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-425796C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDN-0018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-339 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PC-945 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

posaconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTX-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCY-078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0904 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Aspergillosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Aspergillosis and Candidiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Invasive Aspergillosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-FNG - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VL-2397 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspergillosis - Dormant Projects

Aspergillosis - Discontinued Products

Aspergillosis - Product Development Milestones

Featured News & Press Releases

May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day

Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer

Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings

Jan 09, 2017: F2G Receives European Orphan Drug Designation for its Lead Candidate F901318

Dec 13, 2016: SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections

Nov 28, 2016: Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies

Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS

Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections

Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections

Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH

Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors

Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis

Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Aspergillosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Aspergillosis – Pipeline by Amplyx Pharmaceuticals Inc, H1 2017

Aspergillosis – Pipeline by Astellas Pharma Inc, H1 2017

Aspergillosis – Pipeline by Biomar Microbial Technologies, H1 2017

Aspergillosis – Pipeline by Biosergen AS, H1 2017

Aspergillosis – Pipeline by Cidara Therapeutics Inc, H1 2017

Aspergillosis – Pipeline by F2G Ltd, H1 2017

Aspergillosis – Pipeline by Hsiri Therapeutics LLC, H1 2017

Aspergillosis – Pipeline by iCo Therapeutics Inc., H1 2017

Aspergillosis – Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Aspergillosis – Pipeline by Merck & Co Inc, H1 2017

Aspergillosis – Pipeline by Nanomerics Ltd, H1 2017

Aspergillosis – Pipeline by Novabiotics Ltd, H1 2017

Aspergillosis – Pipeline by Pulmatrix Inc, H1 2017

Aspergillosis – Pipeline by Pulmocide Ltd, H1 2017

Aspergillosis – Pipeline by Scynexis Inc, H1 2017

Aspergillosis – Pipeline by Sealife PHARMA GMBH, H1 2017

Aspergillosis – Pipeline by Sigma-Tau SpA, H1 2017

Aspergillosis – Pipeline by Vical Inc, H1 2017

Aspergillosis – Pipeline by Visterra Inc, H1 2017

Aspergillosis – Dormant Projects, H1 2017

Aspergillosis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Aspergillosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports